🟠 Moderate Evidence
Vitamin B12 deficiency can cause serious neurological damage even when routine blood tests appear entirely normal, according to landmark research published in the New England Journal of Medicine. In a cohort of patients with confirmed B12-related neuropsychiatric damage, 28% had no anaemia or macrocytosis on standard screening tests, meaning their blood counts were completely normal despite active nerve tissue injury.
Key takeaways
- 28% of patients with B12-related neuropsychiatric damage had no anaemia or macrocytosis on routine blood tests
- Standard serum B12 tests measure both active and inactive B12 fractions, missing 70-90% of functionally deficient patients
- Methylmalonic acid testing is more specific, elevated in 98.4% of confirmed B12-deficient patients
- B12 deficiency can progress silently to irreversible nerve damage if detected late
B12 deficiency: when screening misses neurological damage
Percentage of B12-deficient patients with normal vs abnormal standard blood parameters
Source: Lindenbaum et al., NEJM 1988; Obeid et al., Mol Nutr Food Res 2015 | Georgian Medical Journal News
How B12 works in two separate compartments
Vitamin B12 (cobalamin) functions as a cofactor for two critical enzymes that operate in different cellular locations, and they can fail independently. According to research by Lindenbaum and colleagues in the NEJM, one enzyme operates in the cytoplasm and recycles folate, directly protecting blood cell production. The other enzyme functions in the mitochondria, where it maintains myelin sheath integrity and fuels cellular energy production.
The clinical consequence is that B12 deficiency can damage nerve tissue through mitochondrial failure while leaving blood cell production relatively intact. This explains why standard clinical tests that focus on blood parameters miss the majority of patients with active neurological injury.
Standard serum B12 testing combines active and inactive fractions
The most widely used serum B12 test measures total B12 concentration, but this creates a fundamental diagnostic problem. According to research published in Molecular Nutrition & Food Research, only 10–30% of total serum B12 exists in the active form (holotranscobalamin), which is the fraction that cells can actually absorb. The remaining 70–90% is bound to an inactive carrier protein (haptocorrin) and provides no biological function.
A patient can have a completely normal total serum B12 level—appearing to have adequate stores—while their active B12 fraction is depleted. This measurement error explains the clinical paradox of normal B12 results alongside progressive neurological damage.
Standard serum B12 testing measures both the active fraction (holotranscobalamin, 10–30% of total) and biologically inert haptocorrin-bound B12. Patients can test normal and still be functionally deficient.
— Obeid et al., University of Bonn (Molecular Nutrition & Food Research, 2015)
Methylmalonic acid: the more specific diagnostic marker
Methylmalonic acid (MMA) is a metabolic byproduct that accumulates when B12 is unavailable to run the mitochondrial enzyme. Research led by Obeid and colleagues found that elevated MMA was present in 98.4% of patients with confirmed B12 deficiency. Unlike serum B12, MMA directly reflects the functional B12 status at the cellular level.
For patients presenting with neuropsychiatric symptoms and a normal serum B12 test, measuring MMA (and homocysteine) provides specificity for confirming true B12 deficiency. This metabolic approach reduces diagnostic delays and prevents irreversible nerve damage from being missed by conventional screening.
When B12 and folate are both low, order matters
A critical clinical rule exists when both B12 and folate are deficient: B12 must be corrected first. According to Savage and colleagues in the American Journal of Medicine, if folate is given when B12 is deficient, the folate may correct the anaemia on laboratory tests while allowing B12-dependent nerve damage to continue unchecked. This false reassurance—normal blood counts on lab work—can delay proper B12 treatment and allow neurological injury to progress to irreversibility.
What this means
Frequently asked questions
Can B12 deficiency cause permanent nerve damage?
Yes. If left untreated, B12 deficiency can cause subacute combined degeneration of the spinal cord, a progressive myelopathy that can become irreversible. Early detection and treatment are critical to prevent permanent neurological injury. This is why screening should not rely solely on standard serum B12 tests.
What B12 supplement form is most effective?
Cells absorb all four commercial B12 forms (cyanocobalamin, methylcobalamin, hydroxocobalamin, and adenosylcobalamin) and metabolise them to the same active intermediates. Head-to-head oral trial data comparing forms are limited. While hydroxocobalamin may have theoretical retention advantages, clinical superiority in outcomes has not been established in the evidence base. The most important factor is ensuring adequate dosing and absorption.
Why do routine blood tests miss B12 deficiency?
Standard serum B12 testing measures total B12, which includes both the active form your cells can use (10–30%) and inactive carrier-bound B12 (70–90%). You can appear to have adequate B12 on routine testing while your functional B12 is depleted. Metabolic markers like methylmalonic acid reflect actual cellular B12 status more accurately.
The discovery that standard B12 screening misses up to 28% of patients with active neurological damage has significant clinical implications for diagnosis and monitoring. As awareness of this diagnostic gap spreads, more clinicians are adopting methylmalonic acid testing alongside serum B12 in symptomatic patients. Earlier and more accurate detection could prevent progression to irreversible spinal cord injury in thousands of patients annually.
Source: Lindenbaum et al., New England Journal of Medicine, 1988; Obeid et al., Molecular Nutrition & Food Research, 2015
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
